« Back
Home /
Monensin (sodium)

Monensin (sodium)

Item no.	HY-N0150-10mM
Manufacturer	MedChem Express
CASRN	22373-78-0
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL
Category	Food Safety Antibiotics Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	98.0
Citations	[1]Dayekh K, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014 Nov;13(11):2559-71.\|[2]Tumova L, et al. Monensin inhibits canonical Wnt signaling in human colorectal cancer cells and suppresses tumor growth in multiple intestinal neoplasia mice. Mol Cancer Ther. 2014 Apr;13(4):812-22.\|[3]Youhua Huang, et al. Autophagy Participates in Lysosomal Vacuolation-Mediated Cell Death in RGNNV-Infected Cells. Front Microbiol. 2020 Apr 30:11:790. \|[4]Ariel Savina, et al. Rab11 promotes docking and fusion of multivesicular bodies in a calcium-dependent manner. Traffic. 2005 Feb;6(2):131-43. Adv Healthc Mater. 2024 Dec 1:e2402976.\|bioRxiv. 2023 Jun 25.\|bioRxiv. 2023 Sep 12.\|bioRxiv. 2024 Jul 27:2024.07.25.605164.\|Cell Host Microbe. 2025 Jan 8;33(1):119-136.e11.\|Front Microbiol. 2020 Apr 30;11:790.\|Int Immunopharmacol. 2023 Sep 1;124(Pt A):110865.\|J Exp Med. 2023 Mar 6;220(3):e20221316.\|Nat Commun. 2022 Jul 22;13(1):4255.\|Nat Commun. 2025 Mar 10;16(1):2368.\|Research Square Preprint. 2023 Aug 31.\|Signal Transduct Target Ther. 2024 Dec 30;9(1):367.\|AAPS PharmSciTech. 2023 Feb 15;24(2):69.\|Biochem Pharmacol. 2023 Dec 2:115957.\|Clin Exp Immunol. 2023 Dec 26:uxad137.\|Clin Immunol. 2022: 109217.\|Int J Parasitol Drugs Drug Resist. 2023 Aug, 22, 44-51.\|J Exp Clin Cancer Res. 2021 Jan 6;40(1):16.\|Nat Methods. 2023 Dec 4.\|OncoImmunology. 2023 Apr 19.\|Redox Biol. 2022 Aug 27;56:102456.\|Signal Transduct Target Ther. 2023 Jul 17;8(1):273.\|Small. 2021 Nov 1;e2103984.
Smiles	OC[C@@]1(O)[C@H](C)C[C@H](C)[C@]([C@@]2(O[C@]([C@@]3(CC[C@@]([C@]4(O[C@@]5(C[C@H](O)[C@@H](C)[C@@]([H])([C@H]([C@@H](OC)[C@H](C)C(O[Na])=O)C)O5)CC4)C)([H])O3)CC)([H])[C@@H](C)C2)[H])([H])O1
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	Monensin A (sodium)
Shipping Condition	Room temperature
Available
Manufacturer - Type	Natural Products
Manufacturer - Applications	COVID-19-immunoregulation
Manufacturer - Targets	Antibiotic; Apoptosis; Bacterial; Fungal; Na+/H+ Exchanger (NHE); Parasite; Wnt
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	692.85
Product Description	Monensin (Monensin A) sodium, an orally active antibiotic, is an ionophore that mediates Na+/H+ exchange. Monensin sodium is a potent Wnt signaling inhibitor. Monensin sodium causes a marked enlargement of the multivesicular bodies (MVBs) and regulates exosome secretion. Monensin sodium can be used for bacterial, fungal, and parasitic infections research, and shows anticancer effects[1][2][3][4].
Manufacturer - Research Area	Infection; Cancer
Solubility	DMSO: 2 mg/mL (ultrasonic; warming; heat to 60°C)\|Ethanol: 20 mg/mL (ultrasonic)
Manufacturer - Pathway	Anti-infection; Apoptosis; Membrane Transporter/Ion Channel; Stem Cell/Wnt
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-N0150-10mM-safety-datasheet.pdf